Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transient cell-in-cell formation underlies tumor relapse and resistance to immunotherapy

ABSTRACT: This SuperSeries is composed of the SubSeries listed below.

ORGANISM(S): Mus musculus

PROVIDER: GSE164077 | GEO | 2020/12/31

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Transient cell-in-cell formation underlies tumor relapse and resistance to immunotherapy.

Project description:Despite the remarkable successes of cancer immunotherapies, the majority of patients will experience only partial response followed by relapse of resistant tumors. While treatment resistance has frequently been attributed to clonal selection and immunoediting, comparisons of paired primary and relapsed tumors in melanoma and breast cancers indicate that they share the majority of clones. Here, we demonstrate in both mouse models and clinical human samples that tumor cells evade immunotherapy by generating unique transient cell-in-cell structures, which are resistant to killing by T cells and chemotherapies. While the outer cells in this cell-in-cell formation are often killed by reactive T cells, the inner cells remain intact and disseminate into single tumor cells once T cells are no longer present. This formation is mediated predominantly by IFNγ-activated T cells, which subsequently induce phosphorylation of the transcription factors signal transducer and activator of transcription 3 (STAT3) and early growth response-1 (EGR-1) in tumor cells. Indeed, inhibiting these factors prior to immunotherapy significantly improves its therapeutic efficacy. Overall, this work highlights a currently insurmountable limitation of immunotherapy and reveals a previously unknown resistance mechanism which enables tumor cells to survive immune-mediated killing without altering their immunogenicity.

| S-EPMC9489212 | biostudies-literature

Transient cell-in-cell formation underlies tumor relapse and resistance to immunotherapy [B16F10]

Project description:Despite the remarkable successes of cancer immunotherapies, the majority of patients do not exhibit durable responses. While treatment resistance has frequently been attributed to clonal selection and immunoediting, currently, little evidence directly demonstrates this process in epithelial cancers. Here, we demonstrate in both mouse models and human cells, that tumor cells evade immunotherapy by generating transient cell-in-cell structures, which are impenetrable to immune-derived cytotoxic compounds and to chemotherapies. This formation is mediated predominantly by DLL4/DLL1 which are elevated on activated T cells and along with IFNg induces STAT3 phosphorylation in tumors cells. In contrast to previous reports on cell-in-cell formations, here both cells remain alive and disseminate into single tumor cells once T cells are no longer present. Overall, this work highlights a previously unknown resistance mechanism which enable tumor cells to survive immune pressure and provides a new theoretical framework to cancer immunotherapies.

2020-12-31 | GSE164075 | GEO

Transient cell-in-cell formation underlies tumor relapse and resistance to immunotherapy [T cells]

2020-12-31 | GSE164076 | GEO

Transient cell-in-cell formation underlies tumor relapse and resistance to immunotherapy

Project description:Transient cell-in-cell formation underlies tumor relapse and resistance to immunotherapy

| PRJNA688738 | ENA

Transient cell-in-cell formation underlies tumor relapse and resistance to immunotherapy [B16F10]

Project description:Transient cell-in-cell formation underlies tumor relapse and resistance to immunotherapy [B16F10]

| PRJNA688741 | ENA

Transient cell-in-cell formation underlies tumor relapse and resistance to immunotherapy [T cells]

Project description:Transient cell-in-cell formation underlies tumor relapse and resistance to immunotherapy [T cells]

| PRJNA688742 | ENA

Acquired immunotherapy resistance in PDA

Project description:This SuperSeries is composed of the SubSeries listed below.

2023-08-08 | GSE222225 | GEO

Epigenetic silencing of Th1 chemokines shapes tumor immunity, immunotherapy and patient outcome

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

2015-08-11 | E-GEOD-71871 | biostudies-arrayexpress

Genome-wide reprogramming of the chromatin landscape underlies endocrine therapy resistance in breast cancer

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

2013-05-01 | E-GEOD-39418 | biostudies-arrayexpress

Integrated Profiling Reveals Low Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy

Project description:This SuperSeries is composed of the SubSeries listed below.

2021-08-13 | GSE169742 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data